Claire Friedman, MD of Memorial-Sloan Kettering discusses the use of combination therapy for patients with melanoma at the ASCO-SITC Clinical Immuno-Oncology Symposium in Orlando, Florida.
21% Response Rate for Previously Treated Melanoma Using Nivolumab and Ipilimumab
